Silexion net loss widens 44% to USD 3.6 million in Q2 FY26

Reuters2026/08/14 12:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Silexion posted a Q2 net loss of USD 3.6 million, widening 44% year over year, as R&D climbed to USD 2.2 million.
G&A rose 15.4% to USD 1.5 million, while financial results swung to net income of about USD 100,000.
Cash and cash equivalents fell to USD 2.2 million at June 30 from USD 6 million at Dec. 31.
SIL204 entered an active Phase 2/3 trial in locally advanced pancreatic cancer, with the first site initiated at Tel Aviv Sourasky Medical Center in July.
Management said a registered public offering closed Aug. 13 with gross proceeds of about USD 2.5 million, supporting Nasdaq listing compliance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140845PRIMZONEFULLFEED1001257668) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Silexion net loss widens 44% to USD 3.6 million in Q2 FY26

You may also like

Crypto prices